Entrepreneur. Drug hunter. Anti-ideologues, Anti-medical nihilists, Optimist My NGO: https://xitter.cf/t.co/yDWRnOYAyY https://xitter.cf/t.co/SOf8c5OZm6
Joined December 2009
- Tweets37.8K
- Following5.5K
- Followers11.6K
- Likes42.7K
Pinned Tweet
I think Dr. Kurzrock is making a very important point that some people are missing. I asked Claude to create an illustration of what I mean.
For a given cancer, the incidence is relatively fixed, which means the clinical trial patient pool is relatively fixed.
Same pool of patients buys you 24 small ORR trials or 2 big crossover OS trials. Also, a big crossover OS RCT DOES NOT guarantee to give you a BETTER drug - which is the point @Dr_R_Kurzrock is making.
Over lets say 15 years, as a PUBLIC POLICY, what regulatory approval standards will give you the GREATEST IMPROVEMENT IN CANCER CARE?
This is completely DIFFERENT from the question: "which trial design will give you the most ACCURATE assessment of an individual drug's efficacy?"
I also understand the argument that patients will end up paying for drugs that may not work better than SOC. Sure, this may be true at any given snapshot in time, but it is UNLIKELY TO BE TRUE over 24 iterations across 15 years.
Also. I don't buy the argument that you save society money, as the # of patients treated is also relatively fixed. The same $$$ will be spent on the older SOC.
Jing Liang 🇺🇦 retweeted
There are quite a few drugs available in China these days that are not available yet in the US
In January 2025 my mom’s lung cancer spread to her brain. The drug with the best chance of helping her was approved in China but not here.
A doctor told me, almost as an aside, that if she were Chinese she could buy it at a pharmacy.
So I flew to Shanghai and came home with 26 boxes in my luggage. That was 19 months ago. My mom is still here, still working, and in her words has had an amazing three years.
The drug was approved in China in 2023. The FDA approved it in July 2025. It still is not for sale here. I know of at least 30 Americans who have made the same trip.
I have been scared to tell this story because I worried it could cost my mom access to the medicine keeping her alive. But the problem matters more than my silence. These drugs need to be developed and available here, and that means FDA reform.
Art Allen at KFF Health News told our story this week. It also ran in The Washington Post.
kffhealthnews.org/health-ind…
I wonder if Legora eats its own cooking. Did they close their Series E without using any external law firms? :)
From Benchmark leading the seed to an $8.8B valuation in 2.5 years, the Legora team has led the industry by bringing the best products to lawyers around the world. Thrilled to be joined by our friends at Atreides, Baron Capital, Capital Group, Fidelity, JPM, and many others!
PSA for biotech entrepreneurs:
Do not take FDA feedback as gospel. Cross-check it against FDA guidance documents and regulations. If you find inconsistencies, ask the FDA for clarification, citing the relevant guidance documents and regulations.
Quite often, FDA review teams, especially more junior reviewers, are not fully familiar with the agency's own regulations and guidance documents.
Jing Liang 🇺🇦 retweeted
Our "Single-cell multi-omics in IPF & COPD: from atlas to impact" is out! We provide a brief guide to analytic approaches, an overview of how the technologies impact our understanding of the 2 diseases, limitations, future directions.
A 🧵 will follow
publications.ersnet.org/cont…
Jing Liang 🇺🇦 retweeted
Big news for hepatitis B!
After the remarkable success of curing hepatitis C, we are finally making real progress toward a functional cure for hepatitis B!
The FDA just approved bepirovirsen (Hibsago), a first-in-class antisense oligonucleotide, following two phase 3 trials published in NEJM.
About 19% of patients achieved functional cure (sustained HBsAg loss and undetectable HBV DNA after stopping treatment), compared with 0% on placebo.
The treatment involves 6 months of weekly injections and is currently approved for selected patients without cirrhosis.
19% may not sound like much, but I think this is a meaningful step forward.
Hepatitis B is a major cause of cirrhosis and liver cancer (HCC). Hopefully, treatments like this will eventually help us prevent more cases of both.
We still have a long way to go, but this is very encouraging progress!
Jing Liang 🇺🇦 retweeted
The mRNA that gave this person his life back was made on demand. Based on his tumor makeup.
= this is the playbook for CRISPR cures on demand.
"I am here today to uncover my pathway to a successful outcome after a high-risk melanoma diagnosis in 2019."
After a melanoma diagnosis, mRNA cancer vaccine delivered a patient hope — and a path forward bit.ly/4Bnre9O
Jing Liang 🇺🇦 retweeted
(former?) wet lab scientist/mAb engineer here: hypothesis generation was never a major blocker to developing new drugs/advancing science. It's easy to generate low-quality hypotheses. You can waste years chasing bad ideas
It's much harder to ID the good ideas and determine how to best test/implement them with reasonable time and cost
Borrowing from @mfgrp & the late Chris Walsh: often the problem choice constrains feasibility and impact
This dynamic is exactly what we found in our AI in Science: Early Insights piece. Huge uplift in hypothesis generation and computational candidates, but binding bottlenecks moving downstream to verification and testing.
institute.deepmind.com/essay…
Arxiv: ai.google/static/documents/A…
Jing Liang 🇺🇦 retweeted
founder-mode medicine in action
We’ve just made public 125,091 DICOM radiology images from across my cancer journey (link below). The data is both longitudinal and multi-modal, dated and linked to my treatment timeline, so you can compare imaging across initial diagnosis, standard of care, first remission, “founder mode cancer care”, and second remission. It’s viewable in OHIF, the standard open-source viewer used in radiology research.
Given the long history of applying deep learning to radiology, we’re hoping to see a variety of methods and models applied to my data. If you find something interesting, please reach out to [email protected], or if you know a researcher who should see this, tag them below.
Thanks to Terra LaFerriere for organizing these images, and Kamil Slowikowski for building osteosarc.com into the resource it is.
Jing Liang 🇺🇦 retweeted
Turns out that, if you switch payload, there can be activity with ADC sequencing (ORR 30%)
#ESMO26 | Bulumtatug Fuvedotin – Phase II
In metastatic TNBC previously treated with TOP1 inhibitor-based ADCs, the Nectin-4-targeted, MMAE-based ADC bulumtatug fuvedotin achieved an ORR of 30%, with a median PFS of 3.7 months.
Changing both the target antigen and payload appears promising, although the relatively short PFS raises questions about the durability of benefit.
Jing Liang 🇺🇦 retweeted
I'm not a fan of Trump's deal to get more diesel but maybe people should remember how much of Putin's war machine the EU is funding.
Rejuvenate Bio spun out of my lab at Harvard, and I co-founded it. One injection reverses cardiac disease in dogs, with three years of safety data and zero safety issues. They’ve raised $3.2M+ and 1,250+ investors are in, and Kingscrowd ranks the round #1 in the country. It closes soon: wefunder.com/rejuvenatebio
Jing Liang 🇺🇦 retweeted
It’s her little shoes with perfectly tied laces by a mother who loved her that gets me. Now they’re both gone.
A horrific Russian strike in the Kharkiv region. A “shahed” struck people directly – in a park near an ordinary café. Pure atrocity. Six people were killed, including children. A little girl was killed in a stroller – her name was Angelina, she was just over a year old, born in August 2025… Her mother’s name was Inna. She died in the hospital… Another girl who was killed was 11 years old. My condolences to their families and loved ones. Another 14 people were injured, including six more children.
I am grateful to everyone who supports Ukraine under these circumstances and helps us shoot down “shaheds,” shoot down missiles, and stop Russian assaults. These are horrific photos, but behind them are shattered lives and the truth about this war. Lives must be protected. Ukraine needs air defense. You can't think about making money with Russia as long as it continues its asinine war. We ask that sanctions on Russia stay in place as long as the killings continue. We ask America to be strong, and we ask it to apply the Lindsey Graham law. We ask Europe to continue its support. We ask that everything possible be done to bring peace and guarantee security. Ukraine wants peace. It is Russia that has insisted on continuing the killing all this time. The world has enough strength to stop the war. That strength must finally be used – against the murderers.
😂😂The scolding BioX needs and deserves.
I am laughing way harder at this tweet than any normal person should🤣🤣🤣
One month (or so) on @X , a platform unlike any other. Energy, speed, smarts and stupidity.
-The best thing in BioX - Rapid and divergent takes on new clinical data, on balance usually right..wisdom of crowds
-The worst thing on BioX - Shameless replies and reposts pumping your own book, praying for M&A about your favorite name, plane stalking…do people actually think this is how a real drug company or serious investor makes decisions? Maybe it just makes you feel like you have some agency, then ok.